NDA Deficiencies Prolonged Review Of Lunesta Sleep Aid – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Inadequacies in Sepracor's NDA for the insomnia drug Lunesta (eszopiclone) kept FDA from reaching an approval decision during the first review cycle, agency review documents indicate
You may also be interested in...
Complete Submissions Are Key To Good Review Management Principles – FDA
As FDA rolls out its Good Review Management Principles - its attempt to improve FDA's timely review of drug applications through professional best practices - the agency is stressing the importance of sponsors submitting complete applications to facilitate this process
Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate
Unusually strict eligibility criteria in the only long-term trial supporting Sepracor’s Lunesta NDA complicated FDA’s analysis of carcinogenicity risk, one of the major issues in the review.
Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate
Unusually strict eligibility criteria in the only long-term trial supporting Sepracor’s Lunesta NDA complicated FDA’s analysis of carcinogenicity risk, one of the major issues in the review.